# Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults

> **NCT03910972** · PHASE1,PHASE2 · COMPLETED · sponsor: **Baylor College of Medicine** · enrollment: 290 (actual)

## Conditions studied

- Schistosomiasis
- Schistosoma Mansoni

## Interventions

- **BIOLOGICAL:** Sm-TSP-2/Alhydrogel® vaccine
- **BIOLOGICAL:** Sm-TSP-2/Alhydrogel® vaccine plus AP 10-701
- **BIOLOGICAL:** ENGERIX-B Hepatitis B Vaccine

## Key facts

- **NCT ID:** NCT03910972
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-07
- **Primary completion:** 2024-11-13
- **Final completion:** 2024-11-13
- **Target enrollment:** 290 (ACTUAL)
- **Last updated:** 2025-11-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03910972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03910972, "Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03910972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*